Suven Life Sciences completes 100% patient enrolment for Phase-2b MDD trial ahead of schedule
Conducted entirely in the United States, the randomised, double-blind, placebo-controlled trial aims to evaluate the safety and efficacy of Ropanicant across 195 patients at 35 sites over six weeks.
